文献速递核素与放射性配体治疗骨显像与常规 SPECT

用99mTc-GSA闪烁显像在肝肿瘤碳离子放疗前估算治疗后肝脏储备功能

Estimation of post-therapeutic liver reserve capacity using 99mTc-GSA scintigraphy prior to carbon-ion radiotherapy for liver tumors.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-10-04

这项回顾性研究纳入50例接受碳离子放疗的肝肿瘤患者,在治疗前用99mTc-GSA闪烁显像结合Gd-EOB-DTPA增强MRI估算剩余肝脏的最大清除率(GSA-RL),并与治疗后3个月的GSA-Rmax比较。中位GSA-RL为0.393 mg/min,治疗后中位GSA-Rmax为0.369 mg/min(P = .40),两者呈线性关系(R2 = 0.67,P < .0001)。作者认为99mTc-GSA闪烁显像在估算残余肝脏储备功能方面具有潜在临床价值。

要点

  • 治疗前估算的剩余肝脏GSA-RL中位值为0.393 mg/min,治疗后3个月实际GSA-Rmax中位值为0.369 mg/min,两者差异无统计学意义(P = .40)。
  • GSA-RL与治疗后GSA-Rmax呈线性关系:y = 0.05 + 0.84x(R2 = 0.67,P < .0001)。
  • 在肝脏储备功能受损组中,估算值与实际值仍呈线性关系:y = -0.02 + 1.09x(R2 = 0.62,P = .0005)。

核心结论

  • 99mTc-GSA闪烁显像对于估算接受肝肿瘤碳离子放疗患者的残余肝脏储备功能具有潜在临床价值。

研究设计与样本

  • 回顾性研究,纳入2018年12月至2020年9月间接受碳离子放疗的肝肿瘤患者,共50例(平均年龄73岁±11,范围29-89岁,男性35例)。
  • 患者在碳离子放疗前及放疗后3个月接受99mTc-GSA闪烁显像,并在放疗前1个月内接受Gd-EOB-DTPA增强MRI检查。
  • 采用非参数Wilcoxon符号秩检验和线性回归分析比较治疗前GSA-RL与治疗后3个月GSA-Rmax。

主要发现

  • 治疗前估算剩余肝脏的GSA-RL中位值为0.393 mg/min(范围0.057-0.729 mg/min),治疗后3个月GSA-Rmax中位值为0.369 mg/min(范围0.037-0.780 mg/min),两者差异无统计学意义(P = .40)。
  • GSA-RL与治疗后GSA-Rmax的线性回归方程为y = 0.05 + 0.84x(R2 = 0.67,P < .0001)。
  • 在肝脏储备功能受损组中,估算值与实际值的线性回归方程为y = -0.02 + 1.09x(R2 = 0.62,P = .0005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is currently no established imaging method for assessing liver reserve capacity prior to carbon-ion radiotherapy (CIRT) for liver tumors. In order to perform safe CIRT, it is essential to estimate the post-therapeutic residual reserve capacity of the liver. PURPOSE: To evaluate the ability of pre-treatment 99mTc-galactosyl human serum albumin (99mTc-GSA) scintigraphy to accurately estimate the residual liver reserve capacity in patients treated with CIRT for liver tumors. MATERIALS AND METHODS: This retrospective study evaluated patients who were performed CIRT for liver tumors between December 2018 and September 2020 and underwent 99mTc-GSA scintigraphy before and 3 months after CIRT, and gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI within 1 month before CIRT were evaluated. The maximal removal rate of 99mTc-GSA (GSA-Rmax) was analyzed for the evaluation of pre-treatment liver reserve capacity. Then, the GSA-Rmax of the estimated residual liver (GSA-RL) was calculated using liver SPECT images fused with the Gd-EOB-DTPA-enhanced MRI. GSA-RL before CIRT and GSA-Rmax at 3 months after CIRT were compared using non-parametric Wilcoxon signed-rank test and linear regression analysis. RESULTS: Overall, 50 patients were included (mean age ± standard deviation, 73 years ± 11; range, 29-89 years, 35 men). The median GSA-RL was 0.393 [range, 0.057-0.729] mg/min, and the median GSA-Rmax after CIRT was 0.369 [range, 0.037-0.780] mg/min (P = .40). The linear regression equation representing the relationship between the GSA-RL and GSA-Rmax after CIRT was y = 0.05 + 0.84x (R2 = 0.67, P < .0001). There was a linear relationship between the estimated and actual post-treatment values for all patients, as well as in the group with impaired liver reserve capacity (y = - 0.02 + 1.09x (R2 = 0.62, P = .0005)). CONCLUSIONS: 99mTc-GSA scintigraphy has potential clinical utility for estimating the residual liver reserve capacity in patients undergoing carbon-ion radiotherapy for liver tumors. TRIAL REGISTRATION: UMIN000038328, https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000043545 .

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yamazaki K, Nishii R, Mizutani Y, et al. Estimation of post-therapeutic liver reserve capacity using 99mTc-GSA scintigraphy prior to carbon-ion radiotherapy for liver tumors. Eur J Nucl Med Mol Imaging. 2022. PMID: 36192469. doi:10.1007/s00259-022-05985-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。